Scientific, reliable information for patients and the public

Gene Therapy 101 Disease Treatments

Gene Therapy 101

Gene Therapy Basics

Gene therapy has been studied for more than 40 years and can help stop or slow the effects of disease on the most basic level of the human body—our genes. And to understand how it works, we’ll start at the basics.

Different Approaches

Gene therapy, cell therapy and gene editing are fields with a similar goal: To treat disease by changing our bodies at a microscopic level. What do these approaches have in common, and what makes them different?

Developing A Treatment

Gene therapies take years to go from theoretical concepts, to preclinical trials, to clinical trials, and, finally, into actual treatments that can improve the lives of patients. Here we learn about the process of developing a treatment.

Disease Treatments

Huntington's Disease

Huntington’s disease is a genetic disorder caused by a breakdown of nerve cells in the brain. The disease affects an individual’s ability to move, their mood, and how they think.

Parkinson's Disease

Parkinson’s degenerative neurological diseaseis a genetic disease that affects 1 in 100 people over the age of 60 and, over time, causes the death of brain cells, called neurons. However, gene therapy might offer hope for managing symptoms, or even improving the effects of existing medications.

Spinal Muscular Atrophy

Gene therapy to treat SMA is now approved for clinical use in the United States.

X-Linked Myotubular Myopathy

The full story on the first gene therapy clinical trials for X-Linked MTM.


Gene therapy for ALD, MLD and other leukodystrophy diagnoses are in the early stages, but preclinical studies have been promising.

Blood Disorders

Gene therapies for sickle cell disease, beta-thalessemia, and Fanconi anemia all show promise and are at various stages of clinical trials.

Inherited Retinal Diseases

Among the most developed gene therapies, Learn more about available treatments and others on the horizon for LCA, retinitis pegmentosa, choroideremia and more.

More Resources

Additional websites, information, definitions and FAQs for patients, families, advocates, and the public.

The ASGCT Education program is supported by:

ASGCT is solely responsible for the content of the Education program.

ASGCT Policy Summit

November 4 – 6 | Washington D.C.